EMCURE logo

Emcure Pharmaceuticals Limited Stock Price

NSEI:EMCURE Community·₹253.9b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author
Create a narrative

EMCURE Share Price Performance

₹1,339.90
-87.00 (-6.10%)
18.9% undervalued intrinsic discount
₹1,652.50
Fair Value
₹1,339.90
-87.00 (-6.10%)
18.9% undervalued intrinsic discount
₹1,652.50
Fair Value
Price ₹1,339.90
AnalystConsensusTarget ₹1,652.50

EMCURE Community Narratives

AnalystConsensusTarget·Updated
Fair Value ₹1.65k 18.9% undervalued intrinsic discount

Expansion In Chronic Therapies And Emerging Markets Will Thrive

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent EMCURE News & Updates

These 4 Measures Indicate That Emcure Pharmaceuticals (NSE:EMCURE) Is Using Debt Reasonably Well

Sep 27
These 4 Measures Indicate That Emcure Pharmaceuticals (NSE:EMCURE) Is Using Debt Reasonably Well
User avatar

Expansion In Chronic Therapies And Emerging Markets Will Thrive

Expansion in chronic therapies, specialty areas, and emerging markets is driving sustained revenue growth and broader international diversification.

Analyst Estimates: Here's What Brokers Think Of Emcure Pharmaceuticals Limited (NSE:EMCURE) After Its Yearly Report

May 25
Analyst Estimates: Here's What Brokers Think Of Emcure Pharmaceuticals Limited (NSE:EMCURE) After Its Yearly Report

Emcure Pharmaceuticals Limited's (NSE:EMCURE) P/E Is On The Mark

May 16
Emcure Pharmaceuticals Limited's (NSE:EMCURE) P/E Is On The Mark

Emcure Pharmaceuticals Limited Key Details

₹81.8b

Revenue

₹33.4b

Cost of Revenue

₹48.4b

Gross Profit

₹41.0b

Other Expenses

₹7.4b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
39.27
Gross Margin
59.16%
Net Profit Margin
9.10%
Debt/Equity Ratio
22.0%

Emcure Pharmaceuticals Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 
View more competitors

Snowflake Analysis

Flawless balance sheet with high growth potential.

0 Risks
3 Rewards
View Full Analysis

About EMCURE

Founded
1981
Employees
6731
CEO
Satish Mehta
WebsiteView website
www.emcure.com

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.

Market Insight

Header cover image

✨Rare Earths: Tiny Market, Outsized Influence

Richard Bowman avatarRichard Bowman
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Last Week
⚡ Utilities: Defensive Dividends Meet the AI Power Surge

⚡ Utilities: Defensive Dividends Meet the AI Power Surge

Indian Market Performance

  • 7 Days: 1.5%
  • 3 Months: -1.7%
  • 1 Year: -4.7%
  • Year to Date: 0.7%
The market has climbed 1.5% in the last 7 days, lead by the Financials sector with a gain of 2.3%. Over the past year the market is down 4.7%. Earnings are forecast to grow by 16% annually. Market details ›